1
Home
Companies

Day One Biopharmaceuticals

#5899

Rank

$800.7M

Marketcap

US United States

Country

Day One Biopharmaceuticals
Leadership team

Dr. Jeremy Bender M.B.A., Ph.D. (CEO, Pres & Director)

Dr. Samuel C. Blackman M.D., Ph.D. (Co-Founder & Chief Medical Officer)

Ms. Julie Papanek Grant M.B.A. (Co-Founder & Director)

Products/ Services
Biopharma, Biotechnology, Health Care, Pharmaceutical
Number of Employees
50 - 100
Headquarters
South San Francisco, California, United States
Established
2018
Company Registration
SEC CIK number: 0001845337
Traded as
DAWN
Social Media
URL
https://dayonebio.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
History

Day One Biopharmaceuticals was founded in 2016 with the ambition to make meaningful improvements in the lives of patients living with rare diseases. We focus on the development and commercialization of innovative therapies targeting unmet medical needs in rare diseases.

Mission
Our mission is to innovate and develop therapies that have the potential to profoundly improve the lives of patients living with rare diseases such as lysosomal storage disorders, mitochondrial diseases, neurometabolic diseases and other rare genetic diseases.
Vision
We envision a world in which our therapies make a visible, life-changing difference in the health and wellbeing of patients and families living with rare diseases.
Key Team

Mr. Charles N. York II (COO, CFO & Sec.)

Dr. Mike Preigh Ph.D. (Chief of Technology Operations)

Mr. Adam Dubow (Gen. Counsel)

Ms. Jaa Roberson (Chief People Officer)

Dr. Davy Chiodin Ph.D., Pharm.D. (Chief Devel. Officer)

Recognition and Awards
Day One Biopharmaceuticals has been recognized for its commitment to innovation, including a spot on the Fierce Biotech Fierce 15 and both Fierce Pharma and Fierce Medtech Fierce 50 lists
References

https://www.investing.com/equities/dot-therapeutics2

https://finance.yahoo.com/quote/DAWN/profile?p=DAWN

https://www.crunchbase.com/organization/day-one-biopharmaceuticals

https://sec.report/CIK/0001845337

https://companiesmarketcap.com/

https://dayonebio.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Day One Biopharmaceuticals
Leadership team

Dr. Jeremy Bender M.B.A., Ph.D. (CEO, Pres & Director)

Dr. Samuel C. Blackman M.D., Ph.D. (Co-Founder & Chief Medical Officer)

Ms. Julie Papanek Grant M.B.A. (Co-Founder & Director)

Products/ Services
Biopharma, Biotechnology, Health Care, Pharmaceutical
Number of Employees
50 - 100
Headquarters
South San Francisco, California, United States
Established
2018
Company Registration
SEC CIK number: 0001845337
Traded as
DAWN
Social Media
URL
https://dayonebio.com